🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience? Page 3

SURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience?

jason_paloalto Wed, Feb 18, 2026 at 8:14 AM 22 replies 986 viewsPage 3 of 5
pam_columbus
Member
312
1,345
Aug 2024
Columbus, OH
Feb 18, 2026 at 5:45 PM#11
ingrid_STO said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

16 14kevin_tulsa, Dr.PainCLE, mike_mealprep and 13 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Feb 18, 2026 at 9:30 PM#12

Clinical perspective, offered as context rather than as advice. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

17 15alex_tucson, kevin_tulsa, Dr.PainCLE and 14 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Feb 19, 2026 at 1:15 AM#13
sophie_paris said:
It helps to say which part of this you are uncertain about.

I read this differently from sophie_paris, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

18 16LibrarianMeg, bri_stats, pete_manc_UK and 15 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Feb 19, 2026 at 5:00 AM#14

One concrete data point for the thread. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

Last edited: Feb 19, 2026 at 6:00 AM
19 17cory_ATX, lori_vegas, Dr.PulmRoch and 16 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 19, 2026 at 8:45 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.

20 18PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 17 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register